Dr. Emanuele Andreano is currently project leader for the N. gonorrhoeae and COVID-19 projects at the Monoclonal Antibody Discovery Laboratory (MAD Lab), Fondazione Toscana Life Sciences, directed by his mentor Prof. Rino Rappuoli. He obtained his bachelor degree in biotechnology at the University of Siena, Italy, and his master degree in immunobiology at Newcastle University, UK. Following, he moved back to Italy where he started an industrial Doctoral program between the University of Siena and Glaxo Smith Klyne (GSK) Vaccines Siena, Italy, and Rockville (MD), USA. After obtaining his Doctoral degree, Andreano started his postdoctoral training at the MAD Lab, Fondazione Toscana Life Sciences, where he currently covers the position of project leader. During his PhD and postdoctoral training, Andreano gained extensive experience on single cell sorting of memory B cells and isolation, cloning, expression and functional/structural characterization of human monoclonal antibodies. This experience has been used to tackle different pathogens which pose serious threats for global health such as the respiratory syncytial virus (RSV), antimicrobial resistant Neisseria gonorrhoeae, SARS-CoV-2 and more recently the Monkeypox virus. The work that he has performed on SARS-CoV-2 led to the isolation of more than 10,000 thousand human monoclonal antibodies and to the identification of MAD0004J08, one of the most potent monoclonal ever described and evaluated in a phase II/III clinical trial for the treatment of COVID-19. For this work Dr. Andreano was honored with the “COVID-19 heroes award” by his alma mater Newcastle University. Dr. Andreano first authored publications on top tier journals such as PNAS, Cell, Nature Medicine and Nature.